Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Adolescents and Young Adults With Functional Hypothalamic Amenorrhea

NCT06533865 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT06533865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Adolescents and Young Adults With Functional Hypothalamic Amenorrhea
Lead sponsor
Massachusetts General Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
March 19, 2025
Completion date
April 30, 2029
Enrollment
114 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fha (functional hypothalamic amenorrhea)